Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary.
作者信息
Perazella Mark A
机构信息
Department of Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut; and.
Section of Nephrology, Veterans Affairs Connecticut Medical Center, West Haven, Connecticut.
出版信息
Kidney360. 2020 Feb 11;1(3):166-168. doi: 10.34067/KID.0001072019. eCollection 2020 Mar 26.
Abstract
摘要
相似文献
1
Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary.应进行肾活检以明确免疫检查点抑制剂相关急性肾损伤的病因：评论
Kidney360. 2020 Feb 11;1(3):166-168. doi: 10.34067/KID.0001072019. eCollection 2020 Mar 26.
2
Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: PRO.应进行肾活检以明确免疫检查点抑制剂相关急性肾损伤的病因：支持观点。
Kidney360. 2020 Feb 11;1(3):158-161. doi: 10.34067/KID.0001192019. eCollection 2020 Mar 26.
3
Gene Expression Profiling in Kidney Transplants with Immune Checkpoint Inhibitor-Associated Adverse Events.免疫检查点抑制剂相关不良事件的肾移植中的基因表达谱分析。
Clin J Am Soc Nephrol. 2021 Sep;16(9):1376-1386. doi: 10.2215/CJN.00920121. Epub 2021 Jul 9.
4
Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: CON.应进行肾活检以明确免疫检查点抑制剂相关急性肾损伤的病因：反对意见。
Kidney360. 2020 Feb 11;1(3):162-165. doi: 10.34067/KID.0000132020. eCollection 2020 Mar 26.
5
Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury.免疫检查点抑制剂相关急性肾损伤的诊断与管理
Nat Rev Nephrol. 2022 Dec;18(12):794-805. doi: 10.1038/s41581-022-00630-8. Epub 2022 Sep 27.
6
Short-term steroid therapy for immune-checkpoint-inhibitor-related acute kidney injury.免疫检查点抑制剂相关急性肾损伤的短期类固醇治疗
Int Urol Nephrol. 2024 Mar;56(3):1199-1200. doi: 10.1007/s11255-023-03734-7. Epub 2023 Aug 30.
7
Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: COMMENTARY.对于发生免疫检查点抑制剂相关急性肾损伤的患者，再次激发是否合适？：评论
Kidney360. 2021 Sep 17;3(5):806-808. doi: 10.34067/KID.0005592021. eCollection 2022 May 26.
8
The Role of Kidney Biopsy in Immune Checkpoint Inhibitor-Associated AKI.肾活检在免疫检查点抑制剂相关性 AKI 中的作用。
Kidney360. 2022 Jan 13;3(3):530-533. doi: 10.34067/KID.0000232022. eCollection 2022 Mar 31.
9
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.与免疫检查点抑制剂相关的急性肾损伤的临床病理特征
Kidney Int. 2016 Sep;90(3):638-47. doi: 10.1016/j.kint.2016.04.008. Epub 2016 Jun 7.
10
Immune Checkpoint Inhibitor-Associated AKI: Debates in Diagnosis, Management, and Rechallenge.免疫检查点抑制剂相关 AKI：诊断、治疗和再挑战的争议。
Semin Nephrol. 2022 Nov;42(6):151346. doi: 10.1016/j.semnephrol.2023.151346. Epub 2023 May 1.
引用本文的文献
1
The safety of percutaneous renal biopsy for acute kidney injury in metastatic renal cell cancer patients with reduced nephron mass.肾单位数量减少的转移性肾细胞癌患者经皮肾活检对急性肾损伤的安全性
Front Nephrol. 2025 Aug 6;5:1615779. doi: 10.3389/fneph.2025.1615779. eCollection 2025.
2
Pivotal role for typing of renal infiltrates: kidney localisation of a lymphoma presenting as pembrolizumab-associated nephritis. A lesson for the clinical nephrologist.肾脏浸润分型的关键作用：表现为帕博利珠单抗相关肾炎的淋巴瘤的肾脏定位。给临床肾病学家的一个教训。
J Nephrol. 2025 May 12. doi: 10.1007/s40620-025-02246-0.
3
External Validation of an Electronic Health Record-Based Diagnostic Model for Histological Acute Tubulointerstitial Nephritis.基于电子健康记录的组织学急性肾小管间质性肾炎诊断模型的外部验证
J Am Soc Nephrol. 2025 May 1;36(5):859-868. doi: 10.1681/ASN.0000000556. Epub 2024 Nov 5.
4
Clinical features associated with immune checkpoint inhibitor nephritis: a single-center clinical case series.与免疫检查点抑制剂肾炎相关的临床特征：一项单中心临床病例系列研究。
Cancer Immunol Immunother. 2024 Aug 6;73(10):200. doi: 10.1007/s00262-024-03775-6.
5
Biopsy-proven acute tubulointerstitial nephritis in patients treated with immune checkpoint inhibitors: a pooled analysis of case reports.经活检证实的接受免疫检查点抑制剂治疗患者的急性肾小管间质性肾炎：病例报告的汇总分析
Front Oncol. 2023 Oct 23;13:1221135. doi: 10.3389/fonc.2023.1221135. eCollection 2023.
6
Repurposing drugs for diseases associated with podocyte dysfunction.将药物重新用于与足细胞功能障碍相关的疾病。
Kidney Int. 2023 Sep;104(3):455-462. doi: 10.1016/j.kint.2023.05.018. Epub 2023 Jun 7.
7
Acute Kidney Injury in Cancer Immunotherapy Recipients.癌症免疫治疗患者的急性肾损伤。
Cells. 2022 Dec 10;11(24):3991. doi: 10.3390/cells11243991.
8
Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study.过去十年癌症患者的肾活检：一项多中心研究。
J Clin Med. 2022 May 21;11(10):2915. doi: 10.3390/jcm11102915.
9
Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗患者发生急性肾损伤和急性间质性肾炎后的死亡率。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-004421.
10
Rational selection of a biomarker panel targeting unmet clinical needs in kidney injury.针对肾脏损伤中未满足的临床需求合理选择生物标志物组合。
Clin Proteomics. 2021 Feb 22;18(1):10. doi: 10.1186/s12014-021-09315-z.
本文引用的文献
1
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.免疫检查点抑制剂相关 AKI 的临床特征和结局：一项多中心研究。
J Am Soc Nephrol. 2020 Feb;31(2):435-446. doi: 10.1681/ASN.2019070676. Epub 2020 Jan 2.
2
Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?免疫检查点抑制剂相关肾毒性：我们知道什么？我们应该做什么？
Kidney Int. 2020 Jan;97(1):62-74. doi: 10.1016/j.kint.2019.07.022. Epub 2019 Aug 23.
3
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗患者急性肾损伤的发生率、病因和危险因素。
Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1692-1700. doi: 10.2215/CJN.00990119. Epub 2019 Oct 31.
4
Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1.抗程序性死亡蛋白1（PD-1）免疫疗法可能会诱导间质性肾炎，并伴有肾小管上皮细胞中程序性死亡配体1（PD-L1）表达增加。
Kidney Int Rep. 2019 Jun 20;4(8):1152-1160. doi: 10.1016/j.ekir.2019.06.001. eCollection 2019 Aug.
5
Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis.尿液 TNF-α 和 IL-9 用于急性间质性肾炎的临床诊断。
JCI Insight. 2019 May 16;4(10). doi: 10.1172/jci.insight.127456.
6
AKI in Patients Receiving Immune Checkpoint Inhibitors.接受免疫检查点抑制剂治疗患者的急性肾损伤
Clin J Am Soc Nephrol. 2019 Jul 5;14(7):1077-1079. doi: 10.2215/CJN.02340219. Epub 2019 May 2.
7
Present and future of cancer immunotherapy: A tumor microenvironmental perspective.癌症免疫疗法的现状与未来：肿瘤微环境视角
Oncol Lett. 2018 Oct;16(4):4105-4113. doi: 10.3892/ol.2018.9219. Epub 2018 Jul 26.
8
Cardiorenal complications of immune checkpoint inhibitors.免疫检查点抑制剂的心脏肾脏并发症。
Nat Rev Nephrol. 2018 Sep;14(9):571-588. doi: 10.1038/s41581-018-0035-1.
9
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.癌症免疫疗法的肾毒性：过去、现在和未来。
J Am Soc Nephrol. 2018 Aug;29(8):2039-2052. doi: 10.1681/ASN.2018050488. Epub 2018 Jun 29.
10
Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer.肿瘤微环境组成对癌症治疗反应和临床结局的影响。
Future Oncol. 2018 Jun;14(14):1409-1421. doi: 10.2217/fon-2017-0585. Epub 2018 May 31.
Zotero 插件